Infant botulism: case reports and review.
Infant Botulism (IB) is a relatively uncommon, though potentially life-threatening neuroparalytic illness caused by the toxins elaborated by Clostridium botulinum (C botulinum). We describe two cases of Infant Botulism. Both these infants presented with a sepsis-like picture and were unsuspectingly treated with the conventional antibiotics ampicillin and gentamicin. The neuroparalytic syndrome of both infants was probably potentiated by the use of gentamicin. We suggest that cefotaxime be carefully considered instead of gentamicin in the initial management of infants presenting with a sepsis-like clinical picture and associated history of constipation, recent onset of hypotonia, poor feeding and/or drooling. Clinical trials evaluating human Botulism Immune Globulin (BIG) are under way by the California Department of Health. This article comes at a very timely moment because once FDA approved, BIG will be the only specific treatment available for this illness.
Krishna
S
S
Department of Pediatrics, University of Louisville School of Medicine, Louisville, KY, USA.
Puri
V
V
D001906:Botulism / Q000175:diagnosis* / Q000188:drug therapy / Q000503:physiopathology; D002439:Cefotaxime / Q000627:therapeutic use*; D002511:Cephalosporins / Q000627:therapeutic use*; D003937:Diagnosis, Differential; D006801:Humans; D007231:Infant, Newborn; D008297:Male
D002511:Cephalosporins; D002439:Cefotaxime